LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Endologix Inc. (“Endologix” or the “Company”) (Nasdaq: ELGX) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Endologix shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The investigation focuses on whether Endologix and certain of its officers and/or directors violated federal securities laws. On August 2, 2016, CEO John McDermott stated that Endologix would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption (“IDE”) clinical trial, the EVAS FORWARD-IDE Study, given since Endologix had the needed clinical data. On November 16, 2016, Endologix announced that the U.S. Food & Drug Administration requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. When this news was announced, shares of Endologix fell in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.